Intelligence · Clinical Pipeline
NovoThirteen Pipeline
All ClinicalTrials.gov programs at NovoThirteen — phase, modality, and trial IDs.
- Programs
- 13
Quick answer
NovoThirteen has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Decitabine/Tetrahydrouridine A 5/250 mg, Siklos 1 000 mg film-coated tablet., Placebo (NDec)
NovoThirteen
Sickle cell disease
1 trial -
GADOTERIC ACID , PARACETAMOL , coramitug, CETIRIZINE , SODIUM CHLORIDE
NovoThirteen
Participants with transthyretin amyloid cardiomyopathy (ATTR CM)
1 trial -
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.
NovoThirteen
Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.
1 trial -
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy.
NovoThirteen
Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.
1 trial -
Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide
NovoThirteen
Type 2 diabetes and painful diabetic peripheral neuropathy
1 trial -
Placebo A, NNC0487-0111, NNC0487-0111, NNC0487-0111, Placebo C tablets, NNC0487-0111, METFORMIN , NNC0487-0111, NNC0487-0111, NNC0487-0111, DAPAGLIFLOZIN , NNC0487-0111
NovoThirteen
Type 2 Diabetes
1 trial -
Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen
NovoThirteen
Chronic Kidney Disease, with or without Type 2 diabetes, Obesity
1 trial -
Placebo A, Semaglutide B Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen
NovoThirteen
type 2 diabetes
1 trial -
Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo
NovoThirteen
Non-alcoholic steatohepatitis (NASH)
1 trial -
Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen
NovoThirteen
SGA - small for gestational age children
1 trial -
cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, semaglutide, cagrilintide, cagrilintide, cagrilintide semaglutide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, FINERENONE , DAPAGLIFLOZIN , semaglutide, cagrilintide, ENALAPRIL , cagrilintide, cagrilintide, cagrilintide semaglutide
NovoThirteen
Chronic Kidney Disease, Type 2 diabetes
1 trial -
cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, Placebo (zalfermin) + Placebo (semaglutide), semaglutide, Placebo (cagrilintide) + placebo (semaglutide), cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, zalfermin, cagrilintide, cagrilintide
NovoThirteen
alcohol-related liver disease
1 trial -
etavopivat B 10041, etavopivat B 10042
NovoThirteen
Sickle Cell Disease
1 trial
Frequently asked questions
How many pipeline programs does NovoThirteen have?
13 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs